MET amplification + EGFR mutation
|
NSCLC
|
MET amplification + EGFR mutation
|
NSCLC
|
gefitinib + tepotinib Sensitive: C3 – Early Trials
|
gefitinib + tepotinib Sensitive: C3 – Early Trials
|
MET amplification + EGFR mutation
|
NSCLC
|
MET amplification + EGFR mutation
|
NSCLC
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
MET amplification + EGFR mutation
|
NSCLC
|
MET amplification + EGFR mutation
|
NSCLC
|
gefitinib + capmatinib Sensitive: C3 – Early Trials
|
gefitinib + capmatinib Sensitive: C3 – Early Trials
|
MET amplification + EGFR mutation
|
NSCLC
|
MET amplification + EGFR mutation
|
NSCLC
|
osimertinib Resistant: D – Preclinical
|
osimertinib Resistant: D – Preclinical
|